On November 8, 2022, Insilico Medicine, a clinical-stage artificial intelligence-driven drug discovery company, announced a multi-year, multi-target strategic research collaboration with Sanofi. Under the terms of the agreement, the collaboration will leverage Insilico Medicine’s AI platform, Pharma.AI, to advance drug development candidates for up to six new targets. Wilson Sonsini Goodrich & Rosati advised Insilico Medicine on the transaction.

Under the terms of the agreement, Sanofi will pay Insilico Medicine a total of up to $21.5 million covering the upfront and target nomination fees to benefit from Insilico’s end-to-end Pharma.AI platform and gain access to a team of interdisciplinary drug discovery scientists to identify, synthesize, and advance high-quality lead therapeutic compounds up to development candidate stage. Additional payments will be made if key research, development, and sales milestones are met, and could total up to $1.2 billion. The collaboration also establishes mid-single to up to low double-digit tiered royalties for any products developed.

The Wilson Sonsini team that represented Insilico Medicine in the transaction included technology transactions attorneys Alex Key, David Pirko, Chi-Fei Wang, and Miruna Predescu and patent attorney Karen Wong.

For more information, please see Insilico Medicine's press release.